1215323-17-3

Basic information

• Product Name: (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol
• Synonyms: (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol;4-(methylsulfonyl)-2-(trifluoromethyl)benzenemethanol;(2-(trifluoromethyl)-4-(methylsulfonyl)phenyl)methanol
• CAS NO: 1215323-17-3
• Molecular Formula: C₉H₉F₃O₃S
• Molecular Weight: 254.2261696
• Mol File: 1215323-17-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 369.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.423±0.06 g/cm3(Predicted)
• PKA: 13.66±0.10(Predicted)
• CAS DataBase Reference: (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol(1215323-17-3)
• EPA Substance Registry System: (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol(1215323-17-3)

Safety Data

• Hazardous Substances Data: 1215323-17-3(Hazardous Substances Data)

Usage

General Description

(4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol is a chemical compound with the molecular formula C10H11F3O3S. It is a white crystalline solid that is commonly used as a reagent or building block in organic synthesis. (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol has potential applications in pharmaceuticals, agrochemicals, and materials science. It is known for its ability to act as a chiral auxiliary in asymmetric synthesis and as a versatile intermediate in the preparation of various biologically active molecules. (4-(Methylsulfonyl)-2-(trifluoroMethyl)phenyl)Methanol is also used in the synthesis of pharmaceutical drugs and agricultural chemicals due to its unique chemical properties and potential biological activities. Additionally, it is important to handle this compound with care as it may be harmful if ingested or inhaled and can cause irritation to the skin and eyes.

Upstream product

• 1312704-87-2 (4-Methylsulfanyl-2-trifluoromethyl-phenyl)-methanol 
• 1289164-55-1 4-methylsulfanyl-2-(trifluoromethyl)benzaldehyde 
• 90176-80-0 2-(trifluoromethyl)-4-fluorobenzaldehyde 
• 1215310-75-0 4-(methylsulfonyl)-2-(trifluoromethyl)benzaldehyde oxime 

Downstream Products

• 934557-65-0 1-(bromomethyl)-4-(methylsulfonyl)-2-(trifluoromethyl)benzene 
• 872365-14-5 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid 
• 1312704-88-3 1-(4-methanesulfonyl-2-(trifluoromethyl)benzyl)-1H-indazole-5-carbaldehyde 

Relevant articles and documents

PREPARATION OF 2-[2-METHYL-1-[[4-METHYLSULFONYL-2-(TRIFLUORO METHYL)PHENYL]METHYL] PYRROLO[2,3-B]PYRIDIN-3-YL]ACETIC ACID

The present invention relates to a novel compound of Formula IV and use of said compound for the preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoromethyl)phenyl] methyl]pyrrolo[2,3-b]pyridine-3-yl]acetic acid [fevipiprant], Formula IV wherein A is SO2Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.

Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma

Further optimization of an initial DP2 receptor antagonist clinical candidate NVP-QAV680 led to the discovery of a follow-up molecule 2-(2-methyl-1-(4-(methylsulfonyl)-2-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid (compou

AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS

The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.